IPH 62
Alternative Names: IPH-62; IPH62/NKp46 NKCELatest Information Update: 28 Mar 2023
At a glance
- Originator Innate Pharma
- Developer AstraZeneca; Innate Pharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer